Honestly, Flip, I have a lot of trouble understanding what, exactly, you are trying to say on most occasions, let alone whether or not I agree with it. So for now I think I'll just stick to what I'm saying because at least I know what that is. In a nutshell, I am saying that any lack of systemic response observed in distal tumors cannot be attributed to the known high rate of cancer cell mutation.
I'm also characterizing the systemic response as weak. Since, as you pointed out, biopsies are not being obtained for distal tumors, any statements about what might be going on with them remains speculative, but if there were any indications of a strong response I can't see the company not moving heaven and earth to show this as this would be such a huge development. Instead they're apparently moving to multiple site injection, which wouldn't be necessary if there were a strong systemic response seen.
I'm sure you feel free to make your own interpretations - so do I.